Clinical Trials in Boston

Showing 2601-2620 of 17,836 trials

Postoperative Assessment of Platelet-Rich Plasma and Platelet-Rich Fibrin in Temporomandibular Joint Surgery

NCT07359131

The goal of this observational study is to evaluate postoperative outcomes following temporomandibular joint (TMJ) surgery and to compare the effectiveness of intraoperative platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) injections in patients with temporomandibular joint disorders. The study includes adult patients who underwent TMJ surgery and received either PRP or PRF intraoperatively. The main questions this study aims to answer are: Whether intraoperative PRP or PRF injection is associated with differences in postoperative pain intensity and recovery. Whether PRP and PRF differ in their effects on postoperative jaw function, including maximum mouth opening and joint symptoms. If there is a comparison group: Researchers will compare patients who received intraoperative PRP with those who received intraoperative PRF to assess differences in postoperative pain, functional outcomes, and joint-related symptoms. Participants will: Have their existing medical records reviewed retrospectively. Provide postoperative outcome data derived from routine clinical follow-up, with no prospective recruitment or intervention.

Temporomandibular Joint Disorders

Jingping Wang, MD, Ph.D.700 participantsStarted Jan 2026

Boston, Massachusetts, United States

Active Not RecruitingPhase 1< 1 mile

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT05827614

BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). BBI-825 is an oral, potent, selective ribonucleotide reductase (or RNR) small molecule inhibitor. This is a first-in-human, open-label, 2-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with BBI-825 or other select therapies.

Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial Carcinoma+9 more

Boundless Bio, Inc.85 participantsStarted Mar 2023

Los Angeles, California, United States • Santa Monica, California, United States • Denver, Colorado, United States +13 more locations

Postoperative Assessment of Platelet-Rich Plasma and Platelet-Rich Fibrin in Temporomandibular Joint Surgery

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Find Trials by Condition in Boston

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

Evaluation of Sinus Augmentation Bone Healing Using Autograft and Xenograft Compared to Xenograft Alone

Early Postoperative Function After Open Versus Ultrasound-Guided Trigger Finger Release

Study on Allopregnanolone and Depression in Perimenopausal Women

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors